USPTO patent commissioner Focarino to retire in July

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Cookies Settings

USPTO patent commissioner Focarino to retire in July

peggy-focarino-150.jpg

Peggy Focarino has announced she will retire as patent commissioner at the USPTO on July 3

peggy-focarino-150.jpg

Focarino took over as patent commissioner in January 2012, replacing Robert Stoll. She previously was deputy patent commissioner.

Focarino began her career at the USPTO in 1977 as a patent examiner. She was promoted to the senior executive service in 1997.

“Peggy has been an inspiration to so many individuals who have aspired to further American innovation through public service,” said Michelle Lee, director of the USPTO. “Since 1977, when she began her career as a patent examiner, she has proven to be a role model of professionalism and dedication. Her tenure as Commissioner for Patents occurred at a historic moment in the patent system’s 225-year history, during the enactment of the transformative America Invents Act. I am grateful for the opportunity to have worked with her over the last several years, and congratulate her on an extremely successful career.”





more from across site and SHARED ros bottom lb

More from across our site

Julia Bishop is director of IP at Twilio in the US
Hellberg is an IP director at Essity in Sweden
Palińska is the business & IP law lead at CD Projekt Red in Poland
Teemu Itälä is head of legal and compliance for technology standards at Nokia in Finland
David Degen is senior IP counsel at Novartis, Switzerland
Demetrio Roberto Cavicchia is an IP director at Angelini Pharma in Italy
Schwitulla is the head of litigation management at Nokia in Germany
Almeida is the IP group leader at Bosch in Brazil
Amanda Luz is brand protection manager - global at Adidas in the US
Samantak Ghosh is vice president of IP at Avere Therapeutics in the US
Gift this article